Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced ...
Tekla Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks to achieve long-term capital appreciation. The fund invests primarily in companies within the life sciences industry, including biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, and healthcare technology. It also includes investments in the agriculture and environmental management sectors. The fund utilizes fundamental analysis to select growth-oriented businesses, including both established firms and smaller-cap companies, and is managed by abrdn Inc. (following the transition from Tekla Capital Management LLC).
Price Range: 12.87 - 21.32 USD
Pain Points: Provides retail and institutional investors with professional management and diversified exposure to the highly specialized and volatile life sciences and biotechnology sectors, which may be difficult for individual investors to research and manage independently.
Solutions: Active portfolio management, professional fundamental analysis, diversification across various sub-sectors of life sciences (e.g., medical devices, pharma, biotech), and regular income distribution through dividends.
Target Users: Individual investors, financial advisors, wealth managers, and institutional investors looking for a specialized healthcare-focused equity investment.
Supply Chain
Investment Management (abrdn Inc.)Custodial ServicesFund AdministrationMarket Makers and Authorized ParticipantsExchange Listing (New York Stock Exchange)
New York Stock Exchange (NYSE)NYSE:ICEAberdeen Fund Distributors, LLCDestra Capital Advisors LLCFirst Trust Advisors LPSaba Capital Management, L.P.Penserra Capital Management LLCAmplify Investments LLCRaymond James Financial, Inc.NYSE:RJFRetail Shareholders (via brokerage platforms: Schwab, Fidelity, E*Trade, Public.com, etc.)
